Cynata Completes Phase 1 GvHD Clinical Trial Follow-up with Positive Results

NEXT STORY
RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8%
PREV STORY
SOTIO to Present at the LifeSci Partners Summer Symposium
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GBT Reports Recent Business Progress and Provides Third Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) ...

author_avatar
NASDAQ Market News

NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION IN EUROPE AND JAPAN

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION  IN ...

author_avatar
NASDAQ Market News

Precision Therapeutics’ Skyline Medical Division Expands Presence in Australia with Three New STREAMWAY Systems at Wangaratta Hospital in Victoria

MINNEAPOLIS, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or ...

author_avatar
NASDAQ Market News